Back to top
more

QIAGEN (QGEN)

(Delayed Data from NYSE)

$41.86 USD

41.86
1,928,753

-0.03 (-0.07%)

Updated Jun 21, 2024 04:00 PM ET

After-Market: $41.88 +0.02 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 249)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

NuVasive's (NUVA) PRECICE System Gets Expanded FDA Approval

NuVasive's (NUVA) latest receipt of expanded FDA 510(k) approval for PRECICE is likely to fortify its hold in the limb reconstruction and trauma market.

    Abbott Banks on FDA Approvals and Buyouts, Competition Rife

    The market is upbeat about Abbott's (ABT) latest initiatives.

      Bruker (BRKR) at a 52-Week High: What's Driving the Stock?

      The new 52-week high of Bruker (BRKR) came on the back of several new initiatives, the most recent one being the introduction of the new CE-IVD marked Fungiplex Candida fast diagnostic assay.

        LabCorp (LH) Strong on Strategic Planning, Competition Rife

        LabCorp (LH) grows on strong diagnostics business amid softness in the Covance drug development business.

          Henry Schein Closes Merritt Buyout, Expands in Animal Health

          Henry Schein (HSIC) is consistently trying to expand its Animal Health business.

            CryoLife to Buy JOTEC, Preliminary Revenue Result Out for Q3

            CryoLife (CRY) gained access to the $2-billion global market for stent grafts through JOTEC deal.

              QIAGEN Banks on Tie-Ups & Product Launches, Competition Rife

              The market is upbeat about QIAGEN's (QGEN) partnership and co-marketing agreement with CENTOGENE AG to boost its bioinformatics portfolio.

                Is a Beat in Store for Abbott (ABT) This Earnings Season?

                Abbott's (ABT) FreeStyle Libre system receives back-to-back reimbursement approvals in several geographies, which are likely to drive growth in the Diabetes Care sales segment within Medical group.

                  QIAGEN Partners With CENTOGENE, Boosts Bioinformatics Suite

                  QIAGEN (QGEN) makes another encouraging move to expand its advanced bioinformatics portfolio and add additional capabilities, partners CENTOGENE.

                    QIAGEN's QFT-Plus Launch to Boost Molecular Diagnostics Arm

                    QIAGEN (QGEN) strengthens its highest revenue grossing segment with the launch of QuantiFERON-TB Gold Plus in the United States.

                      Abbott-North West London Pathology Expand in Diagnostics

                      Abbott Laboratories' (ABT) collaboration with North West London Pathology to strengthen its steadily growing diagnostics arm.

                        QIAGEN (QGEN) Beats on Earnings & Sales in Q2, Raises View

                        QIAGEN (QGEN) continues to bank on the Molecular Diagnostics space for growth.

                          QIAGEN Strengthens Cancer Research Foothold on New License

                          QIAGEN N.V. (QGEN) has received a worldwide license for biomarkers to be used in identifying patients who may have benefited from immune-oncology (I-O) therapies in cancer treatment.

                            Bristol-Myers Presents Data on Immuno-Oncology Drug Opdivo

                            Bristol-Myers BMY announced that the EC has approved immuno-oncology drug Opdivo for the treatment of locally advanced unresectable or metastatic urothelial carcinoma (mUC) in adults after failure of prior platinum-containing therapy.

                              QIAGEN & Bristol-Myers Squibb Partner on Cancer Research

                              QIAGEN N.V. (QGEN) has made significant advancement in the field of cancer research through the use of its revolutionary next-generation sequencing (NGS) technology.

                                Qiagen Banks on Molecular Diagnostic amid Currency Woes

                                On May 4, we issued an updated research report on leading molecular diagnostic company, Qiagen N.V. (QGEN).

                                  QIAGEN (QGEN) Beats Q1 Earnings Estimates, Retains View

                                  QIAGEN N.V. (QGEN) reported first-quarter 2017 adjusted earnings per share (considering restructuring expenses as one time item) of 22 cents, up 15.8% year over year.

                                    Qiagen (QGEN) Down 2.6% Since Earnings Report: Can It Rebound?

                                    Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                      QIAGEN Releases Favorable GeneReader Results, Expands in NGS

                                      QIAGEN N.V. (QGEN) recently has validated its GeneReader NGS System and published five new independent studies.

                                        QIAGEN Offers JAK2 Kit in US, Grows in Molecular Diagnostics

                                        QIAGEN N.V. (QGEN) launched ipsogen JAK2 RGQ PCR Kit in the U.S, following the Food and Drug Administration's (FDA) approval.

                                          QIAGEN (QGEN) Earnings Meet, Sales Miss Estimates in Q4

                                          QIAGEN N.V. (QGEN) reported fourth-quarter 2016 adjusted earnings per share (excluding restructuring expenses) of 39 cents, up 7.7% year over year.

                                            QIAGEN (QGEN) Buys OmicSoft, Expands Bioinformatics Suite

                                            QIAGEN N.V. (QGEN) recently announced the acquisition of Cary, NC-based OmicSoft Corporation.

                                              Qiagen Poised on Fundamentals, Expansion Plans on Track

                                              On Dec 23, 2016, we issued an updated research report on Netherlands-based molecular diagnostics provider Qiagen NV (QGEN).